Hybrid arteriovenous graft for hemodialysis vascular access in a multicenter registry.
Arteriovenous graft
Hemodialysis
Nitinol-reinforced section
Patency
Vascular hybrid graft
Journal
Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
15
08
2018
accepted:
19
01
2019
pubmed:
10
5
2019
medline:
3
6
2020
entrez:
10
5
2019
Statut:
ppublish
Résumé
The aim of our study was to identify patients' characteristics that predicted a higher chance of arteriovenous graft patency in patients undergoing Gore Hybrid Vascular Graft (GHVG; W. L. Gore & Associates, Flagstaff, Ariz) implantation for hemodialysis access. The GHVG is a polytetrafluroethylene (PTFE) prosthesis with a nitinol-reinforced section (NRS) at the venous end. All consecutive patients undergoing GHVG implantation for hemodialysis access at 10 tertiary referral centers between December 2013 and January 2018 were included in the study and compared with a control group of patients undergoing standard PTFE graft implantation. Selection of patients for hybrid graft implantation was based on the impossibility of autogenous vascular access creation. There were 145 patients included in the GHVG group and 218 in the PTFE group. In the GHVG and the PTFE groups, the mean age was 67 ± 13 years and 65 ± 13 years, and male patients totaled 52% and 46%, respectively. The technical success was 99%. The mean duration of the intervention was 100 minutes (median, 95 minutes; interquartile range, 80-120 minutes). The brachial-axillary configuration was used in the majority of cases (n = 78 [54%]). The 5-cm NRS length was prevalent (n = 108 [75%]). The median NRS oversize was 14% (interquartile range, 0%-21%). Mean follow-up was 13 months (range, 0-55 months). Seventy-one patients (49%) underwent at least one reintervention. Primary, assisted primary, and secondary patency estimates at 12 months were 44% ± 5%, 47% ± 5%, and 65% ± 4% for the GHVG group and 41% ± 4%, 53% ± 4%, and 75% ± 3% for the control group, respectively (P = NS). One-year survival was 90% ± 3%. On multivariable Cox regression analysis, hypotension (P < .001; hazard ratio [HR], 5.8; confidence interval [CI], 2.6-13) and diabetes (P = .024; HR, 1.9; CI, 1.1-3.2) were significant predictors of GHVG loss. A larger graft size was protective against GHVG loss (P = .042; HR, 0.73; CI, 0.54-0.99). The 10-cm-long graft showed a tendency toward improved patency but did not reach statistical significance (P = .074; HR, 0.48; CI, 0.21-1.07). Diabetes and hypotension were predictors of loss of hybrid arteriovenous access. Smaller diameters of NRS were more prone to thrombosis, whereas the 10-cm length seemed to perform better than the 5-cm one.
Identifiants
pubmed: 31068267
pii: S0741-5214(19)30328-3
doi: 10.1016/j.jvs.2019.01.061
pii:
doi:
Substances chimiques
Polytetrafluoroethylene
9002-84-0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1904-1912.e2Investigateurs
Filippo Benedetto
(F)
Domenico Spinelli
(D)
Narayana Pipitò
(N)
Graziana Derone
(G)
Mirko Menegolo
(M)
Franco Grego
(F)
Matteo Tozzi
(M)
Marco Franchin
(M)
Gabriele Piffaretti
(G)
Patrizio Castelli
(P)
Umberto Marcello Bracale
(UM)
Dalmazio Frigerio
(D)
Andrea Agostinucci
(A)
Antonino Scolaro
(A)
Walter Morale
(W)
Angela Alibrandi
(A)
Carlo Pratesi
(C)
Elena Giacomelli
(E)
Alessandro Alessi Innocenti
(AA)
Carlo Setacci
(C)
Giulia Mazzitelli
(G)
Michele Giubbolini
(M)
Giambattista Gagliardo
(G)
Informations de copyright
Copyright © 2019 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.